Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2...
Cancer
Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China
China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...
Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...
Shyndec’s Generic Cytosar-U Gains Marketing Approval in China
China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...
Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand
Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...
Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance
China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...
Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor...
Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...
Yantai Dongcheng Receives NMPA Approval for F18 PET Imaging Study
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...
JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development
China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...
Mabwell Bioscience Licenses Biosimilars to Russian Firm Binnopharm
China-based Mabwell Bioscience (SHA: 688062) has announced the establishment of a licensing agreement with the...
Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data
Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline...
Aosaikang Receives FDA Approval for ASKG915 Clinical Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...
CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...
HutchMed Initiates Rolling NDA Submission for Elunate to US FDA
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...
Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...